Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avapritinib and Decitabine in SM-AHN
NCT06327685Phase 1Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2024
- Primary completion
- Mar 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of avapritinib in systemic mastocytosis with associated hematologic neoplasm (SM-AHN) (2 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Recommended Phase 2 Dose at 6 months. Started Mar 2024; status: recruiting.
02
Drugs
avapritinib
03
Conditions
systemic mastocytosis with associated hematologic neoplasm (SM-AHN)
Beyond the preview
Go deeper on NCT06327685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06327685.